Munoz L - Search Results

1

DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.

Chen B, McCuaig-Walton D, Tan S, Montgomery AP, Day BW, Kassiou M, Munoz L, Recasens A. Chen B, et al. Among authors: munoz l. Int J Mol Sci. 2021 Apr 13;22(8):4011. doi: 10.3390/ijms22084011. Int J Mol Sci. 2021. PMID: 33924599 Free PMC article.

2

Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation.

Munoz L, Kavanagh ME, Phoa AF, Heng B, Dzamko N, Chen EJ, Doddareddy MR, Guillemin GJ, Kassiou M. Munoz L, et al. Eur J Med Chem. 2015 May 5;95:29-34. doi: 10.1016/j.ejmech.2015.03.003. Epub 2015 Mar 3. Eur J Med Chem. 2015. PMID: 25791676

3

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.

Abbassi R, Johns TG, Kassiou M, Munoz L. Abbassi R, et al. Among authors: munoz l. Pharmacol Ther. 2015 Jul;151:87-98. doi: 10.1016/j.pharmthera.2015.03.004. Epub 2015 Mar 17. Pharmacol Ther. 2015. PMID: 25795597 Review.

4

Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling.

Phoa AF, Browne S, Gurgis FM, Åkerfeldt MC, Döbber A, Renn C, Peifer C, Stringer BW, Day BW, Wong C, Chircop M, Johns TG, Kassiou M, Munoz L. Phoa AF, et al. Among authors: munoz l. Biochem Pharmacol. 2015 Dec 15;98(4):587-601. doi: 10.1016/j.bcp.2015.10.014. Epub 2015 Oct 28. Biochem Pharmacol. 2015. PMID: 26519552

5

Kinase targets in CNS drug discovery.

Gunosewoyo H, Yu L, Munoz L, Kassiou M. Gunosewoyo H, et al. Among authors: munoz l. Future Med Chem. 2017 Mar;9(3):303-314. doi: 10.4155/fmc-2016-0214. Epub 2017 Feb 8. Future Med Chem. 2017. PMID: 28176536

6

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

Zhou Q, Phoa AF, Abbassi RH, Hoque M, Reekie TA, Font JS, Ryan RM, Stringer BW, Day BW, Johns TG, Munoz L, Kassiou M. Zhou Q, et al. Among authors: munoz l. J Med Chem. 2017 Mar 9;60(5):2052-2070. doi: 10.1021/acs.jmedchem.6b01840. Epub 2017 Feb 28. J Med Chem. 2017. PMID: 28206758

7

Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X₇ receptor antagonists.

O'Brien-Brown J, Jackson A, Reekie TA, Barron ML, Werry EL, Schiavini P, McDonnell M, Munoz L, Wilkinson S, Noll B, Wang S, Kassiou M. O'Brien-Brown J, et al. Among authors: munoz l. Eur J Med Chem. 2017 Apr 21;130:433-439. doi: 10.1016/j.ejmech.2017.02.060. Epub 2017 Mar 2. Eur J Med Chem. 2017. PMID: 28279849

8

Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent.

Döbber A, Phoa AF, Abbassi RH, Stringer BW, Day BW, Johns TG, Abadleh M, Peifer C, Munoz L. Döbber A, et al. Among authors: munoz l. ACS Med Chem Lett. 2017 Mar 15;8(4):395-400. doi: 10.1021/acsmedchemlett.6b00483. eCollection 2017 Apr 13. ACS Med Chem Lett. 2017. PMID: 28435525 Free PMC article.

9

Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.

Hoque M, Abbassi RH, Froio D, Man J, Johns TG, Stringer BW, Day BW, Pajic M, Kassiou M, Munoz L. Hoque M, et al. Among authors: munoz l. Pharmacol Res. 2018 Aug;134:166-178. doi: 10.1016/j.phrs.2018.06.023. Epub 2018 Jun 23. Pharmacol Res. 2018. PMID: 29944980

10

Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.

Sokias R, Werry EL, Chua SW, Reekie TA, Munoz L, Wong ECN, Ittner LM, Kassiou M. Sokias R, et al. Among authors: munoz l. Medchemcomm. 2016 Nov 15;8(1):202-210. doi: 10.1039/c6md00523c. eCollection 2017 Jan 1. Medchemcomm. 2016. PMID: 30108706 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,087 results

Search Page